This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Bull of the Day: DaVita Inc. (DVA)
by Benjamin Rains
DaVita has soared over 70% in 2026 to new highs. The dialysis services giant is projected to double its EPS between 2023 and 2027. Even though it's up 3,000% in the past 25 years, DVA trades at value stock levels.
DVANegative Net Change
medical
Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
by Shaun Pruitt
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
LLYPositive Net Change AMZNPositive Net Change AAPLPositive Net Change MSFTNegative Net Change PFEPositive Net Change NVOPositive Net Change AMGNPositive Net Change NVDANegative Net Change
investing large-cap medical pharmaceuticals
Top Analyst Reports for Alphabet, Apple & Micron Technology
by Mark Vickery
Alphabet's AI-driven growth in Search, Cloud and subscriptions is boosting momentum, though spending and legal risks remain in focus.
AAPLPositive Net Change AVBPositive Net Change PEGNegative Net Change MUPositive Net Change SUNegative Net Change CPIXPositive Net Change GOOGLNegative Net Change ASRVPositive Net Change
computers finance internet medical tech-stocks
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
by Ekta Bagri
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
ADMANegative Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now
by Zacks Equity Research
IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.
BAYRYPositive Net Change IQVPositive Net Change ALHCNegative Net Change
medical
Stryker Launches Pangea Plating System in Europe for Fracture Fixation
by Zacks Equity Research
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
SYKNegative Net Change ISRGNegative Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
by Zacks Equity Research
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
SNYPositive Net Change BMYNegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
by Zacks Equity Research
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
by Urbi Guha
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
LIVNNegative Net Change INSPPositive Net Change NPCEPositive Net Change
medical medical-devices
NPCE Explains How NeuroPace's RNS System Makes Money
by Urbi Guha
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
MDTNegative Net Change LIVNNegative Net Change NPCEPositive Net Change
medical medical-devices